Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Earl HM, Hiller L, Vallier AL. et al
PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Lancet 2019;
393 (10191) 2599-2612

Bibliographische Angaben herunterladen

Aufrufen in: